Virtual event 7th April

Asma Naseem, PhD, is a Senior Research Fellow in the Infection, Immunity, and Inflammation Department at University College London’s Great Ormond Street Institute of Child Health. Her research focuses on advancing innovative gene therapy and genome-editing technologies to develop transformative treatments for rare diseases, particularly primary immunodeficiencies and neurodegenerative lysosomal storage disorders. By leveraging cutting-edge gene-editing and delivery tools, she aims to pave the way for novel therapies that significantly improve patient outcomes and provide hope for conditions with limited or no existing treatment options.

LinkedIn

Maria Mirotsou, MSc, PhD, is the Vice President of Discovery Biology at Scribe Therapeutics, where she leads the discovery research teams to advance preclinical therapeutic candidates from concept to IND applications. Maria brings more than 20 years of expertise in cell biology, drug discovery, and translational science. Her track record includes advancing R&D and IND-enabling studies for a diverse range of disease portfolios, leading business development and licensing activities, and managing extensive collaborations with academic institutions and biopharmaceutical companies. Previously, Maria held key roles at Merck Research Laboratories, where she focused on vascular and retinal disorders; at the Astellas Institute for Regenerative Medicine, where she contributed to advancements in regenerative medicine and cell therapy; and at Cenix Bioscience, where she worked on RNAi drug screening. Her early work also involved pioneering cell therapy and cardiovascular genomics at Duke University School of Medicine and Brigham and Women’s Hospital.

Maria earned her PhD in molecular genetics from University College London, an MSc in medical genetics and immunology from Brunel University, and a BSc in biology from Aristotle University of Thessaloniki.

Scribe Therapeutics LinkedIn

Dr. Emma Wang is the Chief Technology Officer at YolTech Therapeutics. Her focus is on advancing the non-viral delivery platform to support in vivo gene therapy development through research in novel lipid discovery, product development, process development, drug product characterisation as well as GMP manufacture. Prior to joining YolTech, Emma held research positions of growing responsibilities at Providence Therapeutics, Beam Therapeutics and Tessera Therapeutics. Emma holds a Ph.D. in Chemistry as a member of Prof. Katharina Landfester's group from Max Planck Institute for Polymer Research in Germany, a M.Eng and B.Eng in Chemical Engineering from McGill University in Canada.

YolTech Therapeutics

Dr. Madison is Chief Scientific Officer, Gene Therapy at Poseida Therapeutics, after joining the Company in 2019 and most recently serving as Vice President, Genetic Engineering. At Poseida, he has played a leading role in advancing allogeneic CAR-T programs and developing key platforms, including the Cas-CLOVER nuclease and site-specific super piggyBac for applications in cell and gene therapies. Prior to Poseida, Dr. Madison was a tenure-track Assistant Professor of Medicine and a National Institutes of Health (NIH)-funded investigator at Washington University in St. Louis, Missouri, and before that was a Postdoctoral Fellow in genetics at the University of Pennsylvania. Earlier in his career, he led R&D efforts at Transposagen Biopharmaceuticals as the Vice President of Research. Dr. Madison holds a B.A. in Biology from Washington University and a Ph.D. in Cell and Molecular Biology from the University of Michigan.

LinkedIn Poseida Therapeutics

Tina Albertson, MD, PhD, is the chief medical officer for Caribou Biosciences and is responsible for strategic leadership of the company’s clinical programmes and the clinical, regulatory, and medical affairs functions. Dr. Albertson brings 15 years of experience leading the development of cellular therapies and biologics. Previously, she was chief medical officer and head of development for Lyell Immunopharma, where she built and led the clinical development function and initiated two Phase 1 clinical trials evaluating CAR-T cell and TIL therapies in solid tumours. Prior to Lyell, Dr. Albertson was vice president of global drug development at Juno Therapeutics, where she led the global development of BREYANZI (lisocabtagene maraleucel) from pre-clinical studies to the BLA filing that ultimately led to the initial FDA approval. She previously served as medical director of clinical development and experimental medicine at Seagen (formerly Seattle Genetics). Dr. Albertson earned her MD from Stanford University and completed a clinical fellowship in paediatric haematology/oncology at Seattle Children’s Hospital and residency in paediatrics at Denver Children’s Hospital. She earned her PhD in cancer biology from the University of Washington and her BS in molecular biology from the University of Oregon.

LinkedIn Caribou Biosciences